Semaglutide is now FDA-approved for MASH — a progressive liver disease affecting over 8 million Americans that previously had no approved pharmacological treatment. The ESSENCE trial results are remarkable. Here's what patients need to know.
What Changed: For decades, NASH (now renamed MASH — metabolic-associated steatohepatitis) was a disease with no FDA-approved pharmacological treatment. Patients were told to lose weight and exercise. In 2024, Novo Nordisk's semaglutide received FDA approval for MASH based on ESSENCE trial data showing 62.9% of patients achieving MASH resolution without worsening fibrosis. This is a watershed moment for hepatology and a major new indication for the GLP-1 drug class.
You may have heard this condition called NASH — non-alcoholic steatohepatitis. In 2023, the hepatology community adopted new nomenclature: MASH (metabolic-associated steatohepatitis) and MASLD (metabolic-associated steatotic liver disease, formerly NAFLD). The name change reflects a better understanding that this is a metabolic disease driven by the same insulin resistance and adiposity that cause type 2 diabetes and cardiovascular disease — not just "fatty liver from not exercising."
The disease spectrum: MASLD is the accumulation of fat in the liver (steatosis) without significant inflammation. MASH is the more serious form — fat plus inflammation, plus hepatocellular damage, plus varying degrees of fibrosis (scarring). MASH can progress to cirrhosis and liver failure, and is now the second-leading cause of liver transplantation in the United States and the fastest-growing indication for transplant overall.
Approximately 38% of American adults have MASLD. Of those, an estimated 20–25% develop MASH — roughly 8–9 million people. Of MASH patients, approximately 20% will progress to cirrhosis if untreated. Until semaglutide's approval, there was no medication proven to halt or reverse this progression.
The ESSENCE trial enrolled adults with confirmed MASH (biopsy-proven) and liver fibrosis stage F2 or F3 (moderate to severe fibrosis, but not yet cirrhosis). Participants received semaglutide 2.4mg weekly or placebo for 72 weeks.
Primary endpoints and results:
These numbers are remarkable in context. MASH has historically been resistant to pharmacological treatment — multiple large trials of other drug classes showed modest or inconsistent results. The magnitude of MASH resolution with semaglutide in ESSENCE exceeds what was achieved by bariatric surgery in early surgical studies, which had been the only intervention reliably shown to reverse advanced MASH.
GLP-1 receptors are expressed in the liver, and semaglutide appears to act both directly and indirectly on hepatic disease. The mechanisms include:
The dual weight-dependent and direct hepatic mechanisms likely explain why semaglutide's MASH results are more impressive than would be predicted from weight loss alone — similar to the sleep apnea story, where direct biological effects appear to add to the mechanically-mediated benefits.
Discuss MASH or fatty liver with your provider and explore whether semaglutide therapy is appropriate for you.
MASH is dramatically underdiagnosed because it is typically silent until advanced stages. Many patients discover they have significant liver disease incidentally on imaging done for other reasons, or through elevated liver enzymes on routine bloodwork. High-risk groups who should discuss MASH screening with their physician include:
Diagnosis of MASH historically required a liver biopsy — invasive and impractical for screening. Non-invasive alternatives now include FIB-4 index (calculated from routine bloodwork), liver stiffness measurement by FibroScan elastography, and MRI-based liver fat quantification. Hepatologists are increasingly using these non-invasive tools to identify and stage MASH without biopsy in most cases.
FDA approval of semaglutide for MASH creates another important non-obesity coverage pathway — parallel to the OSA indication for tirzepatide. MASH is a serious progressive liver disease, not a "lifestyle" or weight-loss indication. Commercial insurers who exclude GLP-1s for obesity may be required to cover them when prescribed specifically for MASH, given the FDA-approved indication and the absence of alternative pharmacological treatments.
As with the OSA strategy: document the MASH diagnosis thoroughly (biopsy or non-invasive scoring), have your provider reference the MASH indication specifically in the prior authorization, and appeal denials aggressively. This is a legally distinct indication from obesity treatment and should be evaluated on its own merits by the insurer.
For patients navigating cost regardless of indication, see our compounded GLP-1 price guide and insurance coverage guide.
Elevate Health's intake process evaluates all metabolic comorbidities — not just weight — to create the most appropriate treatment plan.
Explore Elevate Health →Claims sourced from ESSENCE trial publications, FDA approval documents, and peer-reviewed hepatology literature. No Fluff. Just Sources.
Licensed compounding programs